Advertisement
UK markets closed
  • FTSE 100

    8,438.18
    +56.83 (+0.68%)
     
  • FTSE 250

    20,658.87
    +127.57 (+0.62%)
     
  • AIM

    790.36
    +6.66 (+0.85%)
     
  • GBP/EUR

    1.1623
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2519
    -0.0005 (-0.04%)
     
  • Bitcoin GBP

    48,719.41
    -896.52 (-1.81%)
     
  • CMC Crypto 200

    1,268.34
    -89.67 (-6.61%)
     
  • S&P 500

    5,211.21
    -2.87 (-0.06%)
     
  • DOW

    39,411.53
    +23.77 (+0.06%)
     
  • CRUDE OIL

    79.05
    -0.21 (-0.26%)
     
  • GOLD FUTURES

    2,370.30
    +30.00 (+1.28%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,756.86
    +70.26 (+0.38%)
     
  • CAC 40

    8,214.35
    +26.70 (+0.33%)
     

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Olema Oncology
Olema Oncology

SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com